A Study of LM-350 in Subjects With Advanced Solid Tumours

Summary

For Phase I Dose Escalation Stage, to assess the safety and tolerability of LM-350 in patients with advanced solid tumors,determine the maximum tolerated dose (MTD) or optimal biological dose (OBD), and explore the relationship between the biomarkers and the anti-tumor activity of LM-350. For Phase II Dose Expansion Stage, to assess the preliminary anti-tumor activity of LM-350 in patients with advanced solid tumors.

Timeline

Start

2025-08-28

Primary completion

2028-06-30

Completion

2030-06-30

Drugs

Indications